Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Consistent Results after Dosing with EP-104GI
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis , Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI
